The Outcome of Six Patients with COVID-19 Infection and Multiple Myeloma.

Elsabah, Hesham; Aldapt, Mahmood B; Taha, Ruba; Soliman, Dina S; Elomri, Halima; Ibrahim, Feryal

Elsabah, Hesham; Aldapt, Mahmood B; Taha, Ruba; Soliman, Dina S; Elomri, Halima; Ibrahim, Feryal.

Elsabah H; Division of Hematology, Department of Medical Oncology, National Center for Cancer Care & Research (NCCCR), Hamad Medical Corporation (HMC), Doha, Qatar.
Aldapt MB; Division of Hematology, Department of Medical Oncology, National Center for Cancer Care & Research (NCCCR), Hamad Medical Corporation (HMC), Doha, Qatar.
Taha R; Division of Hematology, Department of Medical Oncology, National Center for Cancer Care & Research (NCCCR), Hamad Medical Corporation (HMC), Doha, Qatar.
Soliman DS; Department of Laboratory Medicine and Pathology, National Centre for Cancer Care & Research (NCCCR), Hamad Medical Corporation (HMC), Doha, Qatar.
Elomri H; Department of Laboratory Medicine and Pathology, Weill Cornell Medical College (WCMC-Q), Doha, Qatar.
Ibrahim F; Clinical pathology department, National Cancer Institute, Cairo-Egypt.

Mediterr J Hematol Infect Dis ; 12(1): e2020082, 2020.

Article in English | MEDLINE | ID: covidwho-1004838

Keywords

ARDS (acute respiratory distress syndrome); COVID-19; Interlukin6 (IL-6); Multiple myeloma (MM); Tocilizumab

Fulltext

XML

PubMed Links

Search on Google

Full text: Available Collection: International databases Database: MEDLINE Type of study: Prognostic study Language: English Journal: Mediterr J Hematol Infect Dis Year: 2020 Document Type: Article Affiliation country: MJHID.2020.082

Similar

MEDLINE

LILACS

LIS

Fulltext

XML

PubMed Links

Search on Google